1
|
Dookeran KA, Ferrer K, Sekosan M, Holloway N, McCaskill-Stevens WJ, Gehlert SJ. The influence of sociodemographic factors on breast cancer tumor biology. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.1553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
2
|
Dookeran KA, Dignam JJ, Ferrer K, Sekosan M, Radeke EK, Lad TE, Holloway N, McCaskill-Stevens WJ, Gehlert SJ. Race and the influence of p53 as a marker of prognosis in women of lower SES with breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.10590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
3
|
Dookeran KA, Dignam J, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S. p53 as a marker of prognosis in African American (AA) women with breast cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e22119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22119 Background: Prior reports suggest that p53 may be of prognostic value in AA women with breast cancer. However, it remains to be determined whether p53 status would add prognostic value beyond the commonly used factors of stage and Intrinsic Subtype Classification (subtype). We evaluated p53 status as a prognostic factor among AA women treated at an urban community hospital. Methods: Cox proportional hazards regression models [results reported as hazard ratios (HR) with 95% confidence intervals (CI)] were used to select and evaluate prognostic factors [including stage, age, tumor grade of differentiation (grade), p53 status, subtype, & ER/PR status] for all-cause mortality in 331 consecutively treated AA women with breast cancer [42 months follow-up] and known subtype [luminal A = ER+, &/or PR+, & HER2-; luminal B = ER+, &/or PR+, & HER2+; HER2+ = ER-, PR-, & HER2+; basal = ER-, PR-, HER2-, cytokeratin (CK) 5/6+ &/or HER1+; & unclassified = negative for all 5 markers] and p53 [Pab1801 antibody] immunohistochemical status. Results: Tumors in 28% of women were p53+ and there were no chemotherapy and radiation treatment differences according to p53 status. However, 59% of p53+ women were ER/PR negative [Odds Ratio (OR), 0.37; 95% CI, 0.22–0.54; p=0.0003] and hence endocrine therapy was significantly less frequent in p53+ women [OR, 0.40; 95% CI, 0.23–0.69; p=0.0008]. p53+ tumors were also significantly more likely to be grade 3 [OR, 4.35; CI, 1.33–14.14; p=0.013]. Baseline prognostic factors were: stage [(II-IV/I) HR, 2.29; 95% CI, 1.86–2.81; p<0.0001]; age [HR, 1.003 per year; 95% CI, 0.99–1.02; p=0.697]; grade [(high/low) HR, 1.70; 95% CI, 1.22–2.37; p=0.0008]; p53 status [(±) HR, 1.76; 95% CI, 1.15–2.72; p=0.012]; subtype [(all other/luminal A) HR, 1.33; 95% CI, 1.14–1.55; p=0.0004]; ER/PR status [(±) HR, 0.47; 95% CI, 0.32–0.69; p=0.0001]. Cox multivariable models indicated that p53 status [HR, 1.59; 95% CI, 1.01–2.51; p=0.044] remained a significant prognostic factor when considered with stage [HR, 2.20; 95% CI, 1.71–2.84; p<0.001] and subtype [HR, 1.24; 95% CI, 1.04–1.49; p=0.016] and the other above-mentioned factors. Conclusions: Study results indicate that p53 status should be included with stage and subtype as markers to assess prognosis in AA women with breast cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. A. Dookeran
- Cancer Foundation for Minority-Underserved Populations, Chicago, IL; University of Chicago, Chicago, IL; Stroger Hospital, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - J. Dignam
- Cancer Foundation for Minority-Underserved Populations, Chicago, IL; University of Chicago, Chicago, IL; Stroger Hospital, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - K. Ferrer
- Cancer Foundation for Minority-Underserved Populations, Chicago, IL; University of Chicago, Chicago, IL; Stroger Hospital, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - M. Sekosan
- Cancer Foundation for Minority-Underserved Populations, Chicago, IL; University of Chicago, Chicago, IL; Stroger Hospital, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - W. McCaskill-Stevens
- Cancer Foundation for Minority-Underserved Populations, Chicago, IL; University of Chicago, Chicago, IL; Stroger Hospital, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - S. Gehlert
- Cancer Foundation for Minority-Underserved Populations, Chicago, IL; University of Chicago, Chicago, IL; Stroger Hospital, Chicago, IL; National Cancer Institute, Bethesda, MD
| |
Collapse
|
4
|
Dookeran KA, Wang Y, Gao X, Ferrer K, Sekosan M, Lukaszczyk B, Radeke EK, McCaskill-Stevens W, Zaren HA, Gehlert S. p53 as an additional marker to the intrinsic subtype classification as a method to further stratify breast cancer survival in African American (AA) women. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.22007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
5
|
Nathan S, Patel P, Gaddh M, Yim B, Zayat V, Ferrer K, Sekosan M, Samuel J. Clinical presentation characteristics and prognosis of urban, minority patients presenting with triple-negative breast cancer: An observational 5-year case review. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
6
|
Dookeran KA, Wang Y, Gao X, Ferrer K, Sekosan M, DeLaTorre R, Radeke E, McCaskill-Stevens W, Zaren H. Absence of racial predilection for aggressive tumor phenotype among low socio-economic status women with breast cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.10554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10554 Background: Survival disparity for African-American (AA) women with breast cancer has been associated with more frequent aggressive tumor phenotype, manifested as higher stage, high grade and negative estrogen/progesterone receptor (ER/PR) status. However, AAs more often have low socioeconomic status (SES), and other studies suggest that low SES, not simply race, is associated with these prognostic features. We hypothesized that low SES AAs and non-AAs with breast cancer would demonstrate similar aggressive tumor phenotype and prognosis. Methods: Variables were analyzed for 538 consecutive low SES women treated between 1/00–12/05. Comparison between racial groups was done with independent t-test & Chi-square test. Associations were examined with logistic-regression, and compared as odds ratios (OR) & 95% confidence intervals (CI). Survival was computed using Log-rank test & Kaplan-Meier method. Results: At median follow-up of 32 months, there were 335 AAs & 203 non-AAs. No significant differences occurred between racial groups for tumor size & grade, node status, stage, ER/PR status, and frequency of survival events. HER2+ status was more frequent in non-AAs (25.1% vs. 17.9% AAs; p=0.048). No significant differences occurred between races for treatment with surgery, chemo & endocrine therapy, however radiation was more common in non-AAs (73.4% vs. 62.2% AAs; p=0.012) but AAs were significantly older (p=0.0001) and had more comorbid disease (p=0.0001). See Table for prevalence of aggressive tumor features. Age-adjusted logistic-regression showed no racial predilection for negative ER/PR, high grade and higher stage, but AAs were less likely to be HER2+ (OR=0.644; 95% CI=0.415–1.00; p=0.05). Log-rank tests showed no differences between racial groups for age & stage-specific disease-free & overall survival. Conclusions: These results confirm that among similar low SES women with breast cancer, there is no racial predilection for aggressive tumor phenotype and poor prognosis. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- K. A. Dookeran
- Cancer Foundation Minority-Underserved Populations, Chicago, IL; MBCCOP Stroger Hospital, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - Y. Wang
- Cancer Foundation Minority-Underserved Populations, Chicago, IL; MBCCOP Stroger Hospital, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - X. Gao
- Cancer Foundation Minority-Underserved Populations, Chicago, IL; MBCCOP Stroger Hospital, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - K. Ferrer
- Cancer Foundation Minority-Underserved Populations, Chicago, IL; MBCCOP Stroger Hospital, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - M. Sekosan
- Cancer Foundation Minority-Underserved Populations, Chicago, IL; MBCCOP Stroger Hospital, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - R. DeLaTorre
- Cancer Foundation Minority-Underserved Populations, Chicago, IL; MBCCOP Stroger Hospital, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - E. Radeke
- Cancer Foundation Minority-Underserved Populations, Chicago, IL; MBCCOP Stroger Hospital, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - W. McCaskill-Stevens
- Cancer Foundation Minority-Underserved Populations, Chicago, IL; MBCCOP Stroger Hospital, Chicago, IL; National Cancer Institute, Bethesda, MD
| | - H. Zaren
- Cancer Foundation Minority-Underserved Populations, Chicago, IL; MBCCOP Stroger Hospital, Chicago, IL; National Cancer Institute, Bethesda, MD
| |
Collapse
|
7
|
Hess AP, Hamilton AE, Talbi S, Dosiou C, Nyegaard M, Nayak N, Genbecev-Krtolica O, Mavrogianis P, Ferrer K, Kruessel J, Fazleabas AT, Fisher SJ, Giudice LC. Decidual stromal cell response to paracrine signals from the trophoblast: amplification of immune and angiogenic modulators. Biol Reprod 2006; 76:102-17. [PMID: 17021345 DOI: 10.1095/biolreprod.106.054791] [Citation(s) in RCA: 216] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
During the invasive phase of implantation, trophoblasts and maternal decidual stromal cells secrete products that regulate trophoblast differentiation and migration into the maternal endometrium. Paracrine interactions between the extravillous trophoblast and the maternal decidua are important for successful embryonic implantation, including establishing the placental vasculature, anchoring the placenta to the uterine wall, and promoting the immunoacceptance of the fetal allograph. To our knowledge, global crosstalk between the trophoblast and the decidua has not been elucidated to date, and the present study used a functional genomics approach to investigate these paracrine interactions. Human endometrial stromal cells were decidualized with progesterone and further treated with conditioned media from human trophoblasts (TCM) or, as a control, with control conditioned media (CCM) from nondecidualized stromal cells for 0, 3, and 12 h. Total RNA was isolated and processed for analysis on whole-genome, high-density oligonucleotide arrays containing 54,600 genes. We found that 1374 genes were significantly upregulated and that 3443 genes were significantly downregulated after 12 h of coincubation of stromal cells with TCM, compared to CCM. Among the most upregulated genes were the chemokines CXCL1 (GRO1) and IL8,CXCR4, and other genes involved in the immune response (CCL8 [SCYA8], pentraxin 3 (PTX3), IL6, and interferon-regulated and -related genes) as well as TNFAIP6 (tumor necrosis factor alpha-induced protein 6) and metalloproteinases (MMP1, MMP10, and MMP14). Among the downregulated genes were growth factors, e.g., IGF1, FGF1, TGFB1, and angiopoietin-1, and genes involved in Wnt signaling (WNT4 and FZD). Real-time RT-PCR and ELISAs, as well as immunohistochemical analysis of human placental bed specimens, confirmed these data for representative genes of both up- and downregulated groups. The data demonstrate a significant induction of proinflammatory cytokines and chemokines, as well as angiogenic/static factors in decidualized endometrial stromal cells in response to trophoblast-secreted products. The data suggest that the trophoblast acts to alter the local immune environment of the decidua to facilitate the process of implantation and ensure an enriched cytokine/chemokine environment while limiting the mitotic activity of the stromal cells during the invasive phase of implantation.
Collapse
Affiliation(s)
- A P Hess
- Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California 94143-0132, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Dookeran KA, Ferrer K, Sekosan M, Gao X, Wang Y, De La Torre R, Lukaszczyk B, Diaz de Leon L, Roman G, Zaren HA. p53 expression in breast cancer is more likely to predict survival in African-American than Hispanic or white women. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10001 Background: Abnormal nuclear accumulation of p53 protein may predict poorer survival & aggressive tumor biology in African-American (AA) women with breast cancer. We hypothesized that compared to Hispanics or whites, survival would be worse for AA women with p53 positive tumors. Methods: Tumors from 195 consecutive AA, 46 Hispanic & 52 white women were evaluated for p53 expression with IHC, using antibody Pab1801 on paraffin embedded tissue, at the SHCC MBCCOP, in Chicago. Staining was scored on the UK Receptor Group 0–8 system with score ≥2 read as positive. Survival was computed by the Kaplan-Meier method & correlated with p53 expression. Univariate analyses were done with two-sided log-rank test & multivariate analysis was done with Cox proportional-hazards model. Results: There were no significant differences between racial groups regarding tumor size, grade, node status, stage, estrogen receptor (ER) status, treatment & p53 expression. Hispanics were significantly younger (p=0.014). For AA, Hispanic & white women respectively, p53 expression was 29.2%, 34.8% & 18.8%. High grade (p=0.0001) & negative ER status (p=0.006) were significantly associated with p53 expression in AA women; similar results were seen in whites (p=0.014 & p=0.031 respectively), however although the trend for grade was similar, only negative ER status was significantly associated with p53 expression in Hispanics. AA women with p53 positive tumors had significantly worse survival compared to AA women with p53 negative tumors (Hazard Ratio=1.945; 95% CI=1.040–3.638; p=0.037). However, comparison of survival between races for women with p53 positive tumors (p=0.793) and also for women with p53 negative tumors (p=0.4027) was not different. Multivariate analysis demonstrated that there was no interaction (p=0.523) between p53 expression & stage as predictors of poor survival in AA women. Conclusions: Analyses between racial groups demonstrated that AA, Hispanic & white women with breast tumors with abnormal p53 expression had similar associations with high tumor grade, negative ER status and survival. However within racial groups, abnormal p53 expression was only able to predict significantly worse survival in AA women. This association appeared to be independent of stage. [Table: see text]
Collapse
Affiliation(s)
- K. A. Dookeran
- University of Illinois, Chicago, IL; MBCCOP Stroger Hospital of Cook County, Chicago, IL
| | - K. Ferrer
- University of Illinois, Chicago, IL; MBCCOP Stroger Hospital of Cook County, Chicago, IL
| | - M. Sekosan
- University of Illinois, Chicago, IL; MBCCOP Stroger Hospital of Cook County, Chicago, IL
| | - X. Gao
- University of Illinois, Chicago, IL; MBCCOP Stroger Hospital of Cook County, Chicago, IL
| | - Y. Wang
- University of Illinois, Chicago, IL; MBCCOP Stroger Hospital of Cook County, Chicago, IL
| | - R. De La Torre
- University of Illinois, Chicago, IL; MBCCOP Stroger Hospital of Cook County, Chicago, IL
| | - B. Lukaszczyk
- University of Illinois, Chicago, IL; MBCCOP Stroger Hospital of Cook County, Chicago, IL
| | - L. Diaz de Leon
- University of Illinois, Chicago, IL; MBCCOP Stroger Hospital of Cook County, Chicago, IL
| | - G. Roman
- University of Illinois, Chicago, IL; MBCCOP Stroger Hospital of Cook County, Chicago, IL
| | - H. A. Zaren
- University of Illinois, Chicago, IL; MBCCOP Stroger Hospital of Cook County, Chicago, IL
| |
Collapse
|
9
|
Dookeran KA, Ferrer K, Sekosan M, Sciupokiene E, Gao X, Wang Y, Lukaszczyk B, Diaz de Leon L, de la Torre R, Zaren HA. p53 expression predicts poorer survival in African-American women with breast cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. A. Dookeran
- MBCCOP Stroger Hosp Cook County & Surg Onc UIC, Chicago, IL
| | - K. Ferrer
- MBCCOP Stroger Hosp Cook County & Surg Onc UIC, Chicago, IL
| | - M. Sekosan
- MBCCOP Stroger Hosp Cook County & Surg Onc UIC, Chicago, IL
| | - E. Sciupokiene
- MBCCOP Stroger Hosp Cook County & Surg Onc UIC, Chicago, IL
| | - X. Gao
- MBCCOP Stroger Hosp Cook County & Surg Onc UIC, Chicago, IL
| | - Y. Wang
- MBCCOP Stroger Hosp Cook County & Surg Onc UIC, Chicago, IL
| | - B. Lukaszczyk
- MBCCOP Stroger Hosp Cook County & Surg Onc UIC, Chicago, IL
| | | | - R. de la Torre
- MBCCOP Stroger Hosp Cook County & Surg Onc UIC, Chicago, IL
| | - H. A. Zaren
- MBCCOP Stroger Hosp Cook County & Surg Onc UIC, Chicago, IL
| |
Collapse
|
10
|
Dookeran KA, Gao X, Ferrer K, Sciupokiene E, De La Torre R, Diaz de Leon L, Lukaszczyk B, Zhang S, Sekosan M, Zaren HA. Tumor biology in African-American women with breast cancer treated with preoperative chemotherapy: Lack of pathologic complete response is related to p53 overexpression. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. A. Dookeran
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - X. Gao
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - K. Ferrer
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - E. Sciupokiene
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - R. De La Torre
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - L. Diaz de Leon
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - B. Lukaszczyk
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - S. Zhang
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - M. Sekosan
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - H. A. Zaren
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| |
Collapse
|
11
|
Zaren HA, Sciupokiene E, Mackeviciute A, Gao X, Ferrer K, Wang Y, Zhang S, Sekosan M, Dookeran KA. African-American women with breast cancer treated with preoperative chemotherapy have reduced pathologic complete response rates. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. A. Zaren
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - E. Sciupokiene
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - A. Mackeviciute
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - X. Gao
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - K. Ferrer
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - Y. Wang
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - S. Zhang
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - M. Sekosan
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| | - K. A. Dookeran
- MBCCOP, John H. Stroger Jr. Hospital of Cook County, Chicago, IL
| |
Collapse
|
12
|
Yang S, Fang Z, Gurates B, Tamura M, Miller J, Ferrer K, Bulun SE. Stromal PRs mediate induction of 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of E2. Mol Endocrinol 2001; 15:2093-105. [PMID: 11731611 DOI: 10.1210/mend.15.12.0742] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Progesterone stimulates the expression of 17beta-hydroxysteroid dehydrogenase (HSD) type 2, which catalyzes the conversion of the potent estrogen, E2, to an inactive form, estrone, in epithelial cells of human endometrial tissue. Various effects of progesterone on uterine epithelium have recently been shown to be mediated by stromal PRs in mice. We describe herein a critical paracrine mechanism whereby progesterone induction of 17beta-HSD type 2 enzyme activity, transcript levels, and promoter activity in human endometrial epithelial cells are mediated primarily by PR in endometrial stromal cells. Medium conditioned with progestin-pretreated human endometrial stromal cells robustly increased 17beta-HSD type 2 enzyme activity (2-fold) and mRNA levels (13.2-fold) in Ishikawa malignant endometrial epithelial cells. In contrast, direct progestin treatment of Ishikawa epithelial cells gave rise to much smaller increases in enzyme activity (1.2-fold) and mRNA levels (4-fold). These results suggest that progesterone- dependent paracrine factors arising from stromal cells are primarily responsible for the induction of epithelial 17beta-HSD type 2 expression in the endometrium. We transfected serial deletion mutants of the -1,244 bp 5'-flanking region of the 17beta-HSD type 2 gene into Ishikawa cells. No progesterone response elements could be identified upstream of the 17beta-HSD type 2 promoter. Stromal PR-dependent induction of the 17beta-HSD type 2 promoter was mediated by a critical regulatory region mapped to the -200/-100 bp sequence. Direct treatment of Ishikawa cells with progestin gave rise to a maximal increase in the activity of -200 bp/Luciferase construct only by 1.2-fold, whereas medium conditioned by progestin-pretreated endometrial stromal cells increased promoter activity up to 2.4-fold in a time- and concentration-dependent manner. The stimulatory effect of medium conditioned by progestin-pretreated stromal cells was enhanced strikingly by increasing stromal cell PR levels with the addition of estrogen. This epithelial-stromal interaction was specific for endometrial epithelial cells, since 17beta-HSD type 2 could not be induced in malignant breast epithelial cells by media conditioned with progestin-treated breast or endometrial stromal cells. In conclusion, progesterone regulates the conversion of biologically active E2 to estrone by inducing the 17beta-HSD type 2 enzyme in human endometrial epithelium primarily via PR in stromal cells, which secrete factors that induce transcription mediated primarily by the -200/-100 bp 5'-regulatory region of the 17beta-HSD type 2 promoter.
Collapse
Affiliation(s)
- S Yang
- Division of Reproductive Endocrinology, University of Illinois at Chicago, Chicago, Illinois 60612, USA
| | | | | | | | | | | | | |
Collapse
|
13
|
Bartholomew A, Patil S, Mackay A, Nelson M, Buyaner D, Hardy W, Mosca J, Sturgeon C, Siatskas M, Mahmud N, Ferrer K, Deans R, Moseley A, Hoffman R, Devine SM. Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum Gene Ther 2001; 12:1527-41. [PMID: 11506695 DOI: 10.1089/10430340152480258] [Citation(s) in RCA: 133] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
Human mesenchymal stem cells (MSCs) are capable of differentiating into multiple mesenchymal lineages including chondrocytes, osteocytes, adipocytes, and marrow stromal cells. Using a nonhuman primate model, we evaluated nonhuman primate MSCs as targets for gene therapy. Baboon MSCs (bMSCs) cultured from bone marrow aspirates appeared as a homogeneous population of spindle-shaped cells. bMSCs were capable of differentiating into adipocytes and osteocytes in vitro and chondrocytes in vivo. bMSCs were genetically modified with a bicistronic vector encoding the human erythropoietin (hEPO) gene and the green fluorescent protein (GFP) gene. Transduction efficiencies ranged from 72 to 99% after incubation of MSCs with retroviral supernatant. Transduced cells produced from 1.83 x 10(5) to 7.12 x 10(5) mIU of hEPO per 10(6) cells per 24 hr in vitro before implantation. To determine the capacity of bMSCs to express hEPO in vivo, transduced bMSCs were injected intramuscularly in NOD/SCID mice. In a separate experiment, transduced bMSCs were loaded into immunoisolatory devices (IIDs) and surgically implanted into either autologous or allogeneic baboon recipients. Human EPO was detected in the serum of NOD/SCID mice for up to 28 days and in the serum of five baboons for between 9 and 137 days. NOD/SCID mice experienced sharp rises in hematocrit after intramuscular injection of hEPO-transduced bMSCs. The baboon that expressed hEPO for 137 days experienced a statistically significant (p < 0.04) rise in its hematocrit. These data demonstrate that nonhuman primate MSCs can be engineered to deliver a secreted and biologically active gene product. Therefore, human MSCs may be an effective target for future human gene therapy trials.
Collapse
Affiliation(s)
- A Bartholomew
- Department of Surgery, University of Illinois at Chicago, Chicago, IL 60612, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Devine SM, Bartholomew AM, Mahmud N, Nelson M, Patil S, Hardy W, Sturgeon C, Hewett T, Chung T, Stock W, Sher D, Weissman S, Ferrer K, Mosca J, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001; 29:244-55. [PMID: 11166464 DOI: 10.1016/s0301-472x(00)00635-4] [Citation(s) in RCA: 349] [Impact Index Per Article: 15.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
OBJECTIVE The human bone marrow contains mesenchymal stem cells capable of differentiating along multiple mesenchymal cell lineages. Using a non-human primate model, we sought to determine whether the systemic infusion of baboon-derived mesenchymal stem cells was associated with toxicity and whether these cells were capable of homing to and persisting within the bone marrow. MATERIALS AND METHODS Five baboons (Papio anubis) were administered lethal irradiation followed by intravenous autologous hematopoietic progenitor cells combined with either autologous (n = 3) or allogeneic (n = 2) mesenchymal stem cells that had been expanded in culture. In four of these baboons, the mesenchymal stem cells were genetically modified with a retroviral vector encoding either the enhanced green fluorescent protein gene (n = 3) or the human placental alkaline phosphatase gene (n = 1) for tracking purposes. A sixth animal received only intravenous gene marked autologous mesenchymal stem cells but no hematopoietic stem cells or conditioning irradiation. RESULTS Following culture, baboon mesenchymal stem cells appeared morphologically as a homogeneous population of spindle-shaped cells that were identified by the monoclonal antibodies SH-3 and SH-4. These cells did not express the hematopoietic markers CD34 or CD45. Baboon mesenchymal stem cells isolated from primary culture were capable of differentiating along both adipogenic and osteogenic lineages. There was no acute or chronic toxicity associated with the intravenous infusion of mesenchymal stem cells. In all five recipients of gene marked mesenchymal stem cells, transgene was detected in post-transplant bone marrow biopsies. In two animals receiving autologous mesenchymal stem cells, including the one non-conditioned recipient, transgene could be detected over 1 year following infusion. In one recipient of allogeneic gene marked mesenchymal stem cells, transgene was detected in the bone marrow at 76 days following infusion. CONCLUSION These data demonstrate that baboon mesenchymal stem cells: 1) are not associated with significant toxicity when administered intravenously, 2) are capable of homing to the bone marrow following intravenous infusion, and 3) have the capacity to establish residence within the bone marrow for an extended duration following systemic administration.
Collapse
Affiliation(s)
- S M Devine
- Department of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Abstract
OBJECTIVE Local immunosuppressive factors in the uterine cervix infected by human papillomavirus are felt to facilitate the malignant transformation process. Glycodelin-A is an immunosuppressive peptide found in several tissues of müllerian origin, most notably the pregnant and decidualized endometrium. Its expression in the uterine cervix has not been defined but could theoretically contribute to the immunopermissive environment of the cervix. To determine whether glycodelin-A is found in the cervix we examined the squamous and endocervical epithelia from both normal and neoplastic cervical specimens from 14 women. METHODS Immunohistochemisty identification of glycodelin-A was performed on archival paraffin-embedded sections from 10 hysterectomies and 4 cone biopsies. Sections were evaluated and staining was scored as negative, positive, or strongly positive with a separate score for the squamous and glandular components of the cervix. RESULTS Eleven of 14 cases, 79%, demonstrated positive staining of the squamous epithelium. Glycodelin-positive cases included hisologically normal (n = 4; 3 strongly positive, 1 positive) as well as dysplastic (n = 5; 1 strongly positive, 2 positive, and 2 negative) and malignant squamous cells (n = 5; 1 strongly positive, 3 positive, and 1 negative). Normal glandular epithelia were negative in all cases but 1, which demonstrated significant squamous and tubal metaplasia of the endocervical glands involved. CONCLUSION Glycodelin-A is found in the squamous epithelium of both the histologically normal and the neoplastic cervix. Further characterization of these results will focus on the possible immunosuppressive effect glycodelin-A may have in the cervix.
Collapse
Affiliation(s)
- J P Connor
- Department of Obstetrics and Gynecology, University of Illinois at Chicago, Chicago, Illinois, 60612, USA
| | | | | | | |
Collapse
|
16
|
Carr-Brendel V, Markovic D, Ferrer K, Smith M, Taylor-Papadimitriou J, Cohen EP. Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1. Cancer Res 2000; 60:2435-43. [PMID: 10811121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
The high incidence of breast cancer in women and the severity of the disease have stimulated a need for improved and novel forms of therapy. The product of the MUC-1 gene has been identified as a breast cancer-associated antigen in breast cancer patients. The gene has been cloned and sequenced. Transgenic mice were prepared that express human mucin and are naturally tolerant to the molecule, providing a unique opportunity to investigate immunotherapeutic strategies in experimental animals that might eventually be applied to breast cancer patients. A cell line (410.4) derived from a mouse mammary adenocarcinoma that arose in a BALB/c mouse was transduced with a retroviral vector (R1-MUC1-pEMSVscribe) that encoded MUC-1. After confirmation of the expression of human mucin, the cells (E3) were further modified by transduction with retroviral vectors encoding interleukin (IL)-2, IL-4, IL-12, or IFN-gamma to evaluate the effect of cytokine-secretion on the immunogenic properties of the cells in the MUC-1 transgenic mice. The results indicated that modification of the breast cancer cells to secrete IL-12 reduced and at times eliminated the tumorigenic growth properties of the cells. Under similar circumstances, progressively growing tumors formed in MUC-1 transgenic mice that received injections of unmodified E3 cells or with E3 cells modified to secrete IL-2, IL-4, or IFN-gamma. Immunity to breast cancer developed in MUC-1 transgenic mice that had rejected IL-12-secreting E3 cells because the animals were resistant to challenge with (non-cytokine-secreting) E3 cells. In vitro analyses confirmed the presence of T cell-mediated cytotoxicity toward the breast cancer cells in MUC-1 transgenic mice immunized with the IL-12-secreting cells. Our data obtained in a unique animal model system point toward an analogous form of therapy for breast cancer patients.
Collapse
Affiliation(s)
- V Carr-Brendel
- Department of Microbiology and Immunology, University of Illinois, Chicago 60612, USA
| | | | | | | | | | | |
Collapse
|
17
|
Connor JP, Ferrer K, Kane JP, Goldberg JM. Evaluation of Langerhans' cells in the cervical epithelium of women with cervical intraepithelial neoplasia. Gynecol Oncol 1999; 75:130-5. [PMID: 10502439 DOI: 10.1006/gyno.1999.5559] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVE Cervical infection with human papillomavirus (HPV) results in a more permissive environment for malignant transformation. In squamous epithelia the Langerhans' cell (LC) is responsible for antigen presentation. Studies that use S-100 immunostaining demonstrate low LCs in cervical intraepithelial neoplasia (CIN) while those that use other methods have shown normal numbers of LCs. This observation led us to postulate that a defect in S-100 proteins, not a simple decrease in LC number, may be the cause of immune suppression. To evaluate this we identified LCs in the cervix of women with HPV/CIN in a prospective fashion using two antibodies, S-100 and CD1, each targeting a different element of the LC. METHODS Paired biopsies of the cervix were taken, one paraffin embedded for S-100 and the other snap frozen for CD1 staining. LCs were counted and expressed as the number of cells per millimeter of epithelium. Analysis of variance was used to assess differences between counts in normal, low-grade, and high-grade lesions. HPV was tested by hybrid capture. RESULTS S-100 LCs were significantly reduced in dysplasia, LG 8.6 and HG 6.0, compared to normal at 16.7 cells/mm (P = 0.04). S-100 LCs were reduced in HPV-infected cases at 5.9 vs 12.8 cells/mm in HPV negatives (P = 0.02). Acute inflammatory infiltrates were associated with increased S-100 LCs independent of pathology. CD1 LCs were not significantly altered by any parameters tested. CONCLUSIONS HPV/CIN may exert an immunosuppressive effect by decreasing the S-100 LCs. The association of S-100-positive LCs coupled with cervical inflammatory changes suggests an important function of the S-100 proteins in the development of an anti-HPV response.
Collapse
Affiliation(s)
- J P Connor
- Department of Obstetrics and Gynecology, The University of Illinois at Chicago, Chicago, Illinois, 60612, USA
| | | | | | | |
Collapse
|
18
|
Sacanella E, Estruch R, Gaya A, Ferrer K, Fernández-Sola J, Alonso JR, Nicolás JM, Urbano-Márquez A. Upregulated expression of VLA proteins and CD29 in peripheral blood lymphocytes of chronic alcoholics without ethanol-related diseases. Alcohol Clin Exp Res 1999; 23:371-5. [PMID: 10069570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
To analyze adhesion molecule expression on peripheral blood mononuclear cells (PBMCs) and on different lymphocyte subpopulations (CD2+, CD8+, CD19+, and CD56+ subsets) in chronic alcoholism, 30 well-nourished chronic alcoholics without ethanol-related diseases and 30 matched controls were included in the study. Adhesion molecules that mediate adhesion to other cells and to extracellular matrix proteins, and whose cellular expression is modified during lymphocyte activation, were selected for study. A detailed clinical evaluation, laboratory analysis, nutritional assessment, and study of adhesion molecule expression was performed. A significant higher expression of CD29 (beta1-integrin) (p = 0.001), VLA-3 (p = 0.002), VLA-4 (p = 0.03), and VLA-5 (p = 0.001) were observed on PBMCs of chronic alcoholics, compared with control subjects, whereas no changes were observed in CD18 (beta2-integrin) and CD50 (ICAM-3) expression. The upregulation of CD29 and VLA proteins only affected T lymphocytes (CD2+/CD8+/CD4+ cells). These data confirm that T cells of chronic alcoholics are basally activated and that changes in adhesion molecule expression on PBMCs may be responsible of disturbances of adhesion processes in chronic alcoholics without ethanol-related diseases.
Collapse
Affiliation(s)
- E Sacanella
- Department of Internal Medicine, Hospital Clinic Universitari, Institut d'Investigació Biomèdica Agusti Pi Sunyer, University of Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Sacanella E, Estruch R, Gaya A, Ferrer K, Fernandez-Sola J, Alonso JR, Nicolas J, Urbano-Marquez A. Upregulated Expression of VLA Proteins and CD29 in Peripheral Blood Lymphocytes of Chronic Alcoholics Without Ethanol-Related Diseases. Alcohol Clin Exp Res 1999. [DOI: 10.1111/j.1530-0277.1999.tb04124.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
20
|
Abstract
BACKGROUND Risk-stratification schemes exist for well-differentiated thyroid carcinoma and include prognostic factors such as age, sex, extent of tumor, size of tumor, and presence of metastasis. Controversy continues, however, over the aggressiveness of initial surgical intervention because of anecdotal experiences of poor clinical outcomes in low-risk patients. Our objective is to determine the prognostic significance of two biologic tumor markers, the p53 gene mutation and CD34 microvessel density (MVD) count, in well-differentiated tumors of thyroid gland. METHODS We selected 38 patients with well-differentiated thyroid carcinomas from the University of Illinois Tumor Registry. Patients had an average clinical follow-up of 10 years. Paraffin-embedded tumor specimens were available for all patients. Immunohistochemistry was performed to identify mutations of the p53 gene (Ab 1801) and to determine the MVD count (CD34). RESULTS There were significant increases in MVD counts within thyroid tumor tissue, when compared with surrounding, normal thyroid tissue. There was no significant correlation noted, however, between increased MVD and histology or recurrence rates. There was a trend toward higher MVD counts in tumor specimens of patients initially seen with metastatic lymphadenopathy. The incidence of p53 mutation expression was 28%, and there was no correlation between p53 status and histology, sex, recurrence rate, or survival. CONCLUSIONS This study supports the concept of tumor neovascularization but fails to correlate MVD with clinical behavior or pathologic features in well-differentiated thyroid carcinoma. Furthermore, we found that the p53 mutation status was not an independent prognosticator of tumor behavior in these lesions.
Collapse
Affiliation(s)
- J D Goldenberg
- Department of Otolaryngology-Head and Neck Surgery, Eye and Ear Infirmary, University of Illinois at Chicago, 60612, USA
| | | | | | | | | | | |
Collapse
|
21
|
Abstract
BACKGROUND Risk-stratification schemes exist for well-differentiated thyroid carcinoma and include prognostic factors such as age, sex, extent of tumor, size of tumor, and presence of metastasis. Controversy continues, however, over the aggressiveness of initial surgical intervention because of anecdotal experiences of poor clinical outcomes in low-risk patients. Our objective is to determine the prognostic significance of two biologic tumor markers, the p53 gene mutation and CD34 microvessel density (MVD) count, in well-differentiated tumors of thyroid gland. METHODS We selected 38 patients with well-differentiated thyroid carcinomas from the University of Illinois Tumor Registry. Patients had an average clinical follow-up of 10 years. Paraffin-embedded tumor specimens were available for all patients. Immunohistochemistry was performed to identify mutations of the p53 gene (Ab 1801) and to determine the MVD count (CD34). RESULTS There were significant increases in MVD counts within thyroid tumor tissue, when compared with surrounding, normal thyroid tissue. There was no significant correlation noted, however, between increased MVD and histology or recurrence rates. There was a trend toward higher MVD counts in tumor specimens of patients initially seen with metastatic lymphadenopathy. The incidence of p53 mutation expression was 28%, and there was no correlation between p53 status and histology, sex, recurrence rate, or survival. CONCLUSIONS This study supports the concept of tumor neovascularization but fails to correlate MVD with clinical behavior or pathologic features in well-differentiated thyroid carcinoma. Furthermore, we found that the p53 mutation status was not an independent prognosticator of tumor behavior in these lesions.
Collapse
MESH Headings
- Adenocarcinoma, Follicular/blood supply
- Adenocarcinoma, Follicular/genetics
- Adult
- Age Factors
- Antigens, CD34
- Biomarkers, Tumor/genetics
- Capillaries/pathology
- Carcinoma/blood supply
- Carcinoma/genetics
- Carcinoma/pathology
- Carcinoma/secondary
- Carcinoma/surgery
- Carcinoma, Papillary/blood supply
- Carcinoma, Papillary/genetics
- Carcinoma, Papillary, Follicular/blood supply
- Carcinoma, Papillary, Follicular/genetics
- Female
- Follow-Up Studies
- Gene Expression Regulation, Neoplastic
- Genes, p53/genetics
- Humans
- Immunohistochemistry
- Incidence
- Lymphatic Metastasis/pathology
- Male
- Middle Aged
- Mutation/genetics
- Neoplasm Recurrence, Local/pathology
- Neoplasm Staging
- Neovascularization, Pathologic/pathology
- Prognosis
- Registries
- Risk Assessment
- Sex Factors
- Survival Rate
- Thyroid Neoplasms/blood supply
- Thyroid Neoplasms/genetics
- Thyroid Neoplasms/pathology
- Thyroid Neoplasms/surgery
- Treatment Outcome
Collapse
Affiliation(s)
- J D Goldenberg
- Department of Otolaryngology-Head and Neck Surgery, Eye and Ear Infirmary, University of Illinois at Chicago, 60612, USA
| | | | | | | | | | | |
Collapse
|
22
|
Gale P, Adeyemi B, Ferrer K, Ong A, Brill AI, Scoccia B. Histologic characteristics of laparoscopic argon beam coagulation. J Am Assoc Gynecol Laparosc 1998; 5:19-22. [PMID: 9454871 DOI: 10.1016/s1074-3804(98)80005-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
STUDY OBJECTIVES To describe histologic effects of laparoscopic argon beam coagulation and determine the extent of tissue necrosis at various power settings and exposure times. DESIGN Prospective experimental analysis (Canadian Task Force classification II-1). SETTING University animal laboratory. Subjects. Adult female domestic pigs. INTERVENTIONS Various power settings (40, 60, 80 W) at increasing exposure times (1, 3, 5 sec) were used during laparoscopic application of argon beam coagulation to different tissues (uterine horn, bladder, ureter, kidney, bowel, liver). Animals were sacrificed within 1 hour of coagulation for histologic tissue preparation. MEASUREMENTS AND MAIN RESULTS Histologic measurements of both depth and lateral extent of electrosurgical tissue effects (mm +/- SD) were ascertained and evaluated statistically by one-way repeated measures analysis of variance. Depth of tissue necrosis was confined to 1 mm or less in uterine horn, bladder, and ureter. Even at highest power settings, bowel had tissue necrosis no greater than 2 mm. Both liver and kidney showed a deeper histologic effect (4-5 mm). The lateral extent of tissue necrosis ranged from 2 mm (ureter) to 15 mm (liver). CONCLUSION Laparoscopic argon beam coagulation results in tissue effects that are dependent on both low power setting and duration of application, as well as on electrical and physical characteristics of target tissue. Thermal tissue penetration can be expected to be less than 2 mm in bowel, bladder, and ureter, and less than 5 mm in kidney and liver, even at 5 seconds of exposure time and at a power setting as high as 80 W. As with all thermal modalities used for hemostasis and tissue coagulation, laparoscopic argon beam coagulation can be performed safely as long as the potential for inadvertent thermal injury is understood.
Collapse
Affiliation(s)
- P Gale
- Department of Obstetrics and Gynecology, University of Illinois at Chicago, 820 South Wood Street (M/C 808), Chicago, IL 60612, USA
| | | | | | | | | | | |
Collapse
|
23
|
Ilekis JV, Connor JP, Prins GS, Ferrer K, Niederberger C, Scoccia B. Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 1997; 66:250-4. [PMID: 9264571 DOI: 10.1006/gyno.1997.4764] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Ovarian cancer is the second most common malignancy of the female reproductive tract. Approximately 50% of ovarian cancers have elevated levels of epidermal growth factor receptor (EGFR). This overexpression is correlated with a poor prognosis for patient survival. Ovarian cancers also express a number of sex steroid receptors. The androgen receptor (AR) is the predominant sex steroid receptor and is expressed in over 80% of ovarian cancers. We investigated whether a relationship exists between EGFR and AR in ovarian cancer. Sixty serous cystadenocarcinomas were analyzed for their relative levels of EGFR and AR by Western blot analysis. Data were analyzed by Student's t test and linear regression analysis for statistical significance. More than 98% of the tumors expressed detectable levels of EGFR, while 65% of the tumors expressed detectable levels of AR. The levels of EGFR (mean +/- SEM) were found to be significantly (P < 0.01) higher in AR+ (516 +/- 15) than in AR- (304 +/- 57) tumors. EGFR levels significantly correlated to AR levels (r = 0.49, P < 0.001). These results demonstrate an association between EGFR and AR levels in ovarian cancer. Whether this association represents a causal or a casual relationship remains to be determined.
Collapse
Affiliation(s)
- J V Ilekis
- Department of Obstetrics and Gynecology, University of Illinois at Chicago, College of Medicine, 60612, USA
| | | | | | | | | | | |
Collapse
|
24
|
Cohen Y, Spirito A, Sterling C, Donaldson D, Seifer R, Plummer B, Avila R, Ferrer K. Physical and sexual abuse and their relation to psychiatric disorder and suicidal behavior among adolescents who are psychiatrically hospitalized. J Child Psychol Psychiatry 1996; 37:989-93. [PMID: 9119945 DOI: 10.1111/j.1469-7610.1996.tb01495.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Adolescents who were psychiatrically hospitalized (N = 105) were classified as sexually abused, physically abused, both sexually and physically abused, or not abused, and studied to determine the prevalence of suicidal behavior and psychiatric disorders. Self-reports of hopelessness, depression, coping, and self-concept were also examined. No difference in suicidal behavior or psychiatric disorder, based on abuse history, was found, with one exception. Adolescents who were sexually abused, particularly those who experienced the most severe sexual abuse, used negative coping strategies more often than those not sexually abused. Findings suggest that symptomatology of adolescents who are psychiatrically hospitalized does not differ markedly based on history of abuse.
Collapse
|
25
|
Abstract
Nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) are relatively rare tumors, which nonetheless constitute 50% of the soft tissue sarcomas seen in the pediatric population. The prognosis for these tumors is good, with 92% of patients in our series alive and 61% free of their disease at 5 years follow-up. The most important prognostic factor among our 35 patients was the grade of the tumor. More than 70% of our patients with grade I or II lesions are disease-free at 5 years, compared to only 39% of patients with grade III lesions. The patients with the best outlook are those who can be treated with surgery alone as the definitive care for this disease. Resection remains the primary treatment modality in NRSTS, whereas, unlike the treatment of rhabdomyosarcomas, the value of radiation therapy and chemotherapy in treating NRSTS remains undefined.
Collapse
Affiliation(s)
- D M McCoy
- Specialized Cancer Center, University of Illinois, Chicago, 60612
| | | | | | | |
Collapse
|
26
|
Elstein M, Ferrer K. The effect of a copper-releasing intrauterine device on sperm penetration in human cervical mucus in vitro. J Reprod Fertil 1973; 32:109-11. [PMID: 4700793 DOI: 10.1530/jrf.0.0320109] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|